Last reviewed · How we verify
Bilaxten oral dispersible tablets — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Bilaxten oral dispersible tablets (Bilaxten oral dispersible tablets) — Humanis Saglık Anonim Sirketi.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Bilaxten oral dispersible tablets TARGET | Bilaxten oral dispersible tablets | Humanis Saglık Anonim Sirketi | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Bilaxten oral dispersible tablets CI watch — RSS
- Bilaxten oral dispersible tablets CI watch — Atom
- Bilaxten oral dispersible tablets CI watch — JSON
- Bilaxten oral dispersible tablets alone — RSS
Cite this brief
Drug Landscape (2026). Bilaxten oral dispersible tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/bilaxten-oral-dispersible-tablets. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab